Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $98.64 in the prior trading day, Abivax ADR (NASDAQ: ABVX) closed at $99.61, up 0.98%. In other words, the price has increased by $0.98 from its previous closing price. On the day, 0.71 million shares were traded. ABVX stock price reached its highest trading level at $100.377 during the session, while it also had its lowest trading level at $96.1.
Ratios:
Our goal is to gain a better understanding of ABVX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.77 and its Current Ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on October 13, 2025, initiated with a Overweight rating and assigned the stock a target price of $142.
On July 23, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $71.
On March 20, 2025, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $12.Morgan Stanley initiated its Equal-Weight rating on March 20, 2025, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 28 ’25 when Sofinnova Crossover I SLP bought 1,200,000 shares for $92.75 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABVX now has a Market Capitalization of 7915473408 and an Enterprise Value of 6360201216. Its current Enterprise Value per Revenue stands at 1055.986 whereas that against EBITDA is -34.259.
Stock Price History:
The Beta on a monthly basis for ABVX is 0.94, which has changed by 8.358634 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, ABVX has reached a high of $108.00, while it has fallen to a 52-week low of $4.77. The 50-Day Moving Average of the stock is 12.47%, while the 200-Day Moving Average is calculated to be 181.82%.
Shares Statistics:
The stock has traded on average 1.09M shares per day over the past 3-months and 1204740 shares per day over the last 10 days, according to various share statistics. A total of 77.83M shares are outstanding, with a floating share count of 68.74M. Insiders hold about 11.68% of the company’s shares, while institutions hold 30.29% stake in the company. Shares short for ABVX as of 1760486400 were 1363331 with a Short Ratio of 1.25, compared to 1757894400 on 1819604. Therefore, it implies a Short% of Shares Outstanding of 1363331 and a Short% of Float of 2.08.
Earnings Estimates
Currently, 1 analysts are dedicated to thoroughly evaluating and rating the performance of Abivax ADR (ABVX) in the stock market.The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.61 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$3.06 and -$3.63 for the fiscal current year, implying an average EPS of -$3.41. EPS for the following year is -$2.92, with 4.0 analysts recommending between -$2.05 and -$3.75.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $1.28M. There is a high estimate of $1.28M for the next quarter, whereas the lowest estimate is $1.28M.
